Change in body weight and treatment outcome in sputum positive pulmonary tuberculosis patients treated under directly observed treatment short-course

Background: Patients with tuberculosis often suffer from severe weight loss and is used as useful marker to predict TB treatment outcome. Hence a study was planned with an objective to determine the change of patient’s body weight over time throughout treatment and to determine whether there was any association with treatment outcome.Methods: This was a retrospective cohort study, planned to be conducted among all smear positive pulmonary tuberculosis patients registered in a Tuberculosis Unit of Pune corporation, during the period of January to December 2015. Body weights of patients were recorded from TB treatment cards at the time of diagnosis, after 2 months of intensive phase of treatment and at the end of treatment. Total 344 cases were enrolled. Chi-Square test and Fisher’s exact test and repeated measure ANOVA test was used for analysis.Results: A bad outcome was more likely among the category II cases as compared to category I, among non-adherent to treatment cases in continuation phase and higher sputum grading at the time of diagnosis i. e. in 3+ sputum smear grading. The weights of the patients at the time of diagnosis, at end of intensive phase and at end of treatment showed statistical significant difference (p<0.0001). The weight gain, more so at end of treatment was significantly associated with good outcome.Conclusions: Weight gain has prognostic significance in patients with tuberculosis and should be considered as a surrogate marker to monitor response to TB treatment especially in developing countries where extensive laboratory tests are not feasible.

Download Full-text

A study of factors affecting weight gain among tuberculosis patients under DOTS in district Amritsar

International Journal of Community Medicine and Public Health ◽

10.18203/2394-6040.ijcmph20184573 ◽

2018 ◽

Vol 5 (11) ◽

pp. 4804

Author(s):

Pooja Sadana ◽

Harpreet Kaur ◽

Vishal Verma

Keyword(s):

Body Weight ◽

Weight Gain ◽

Body Weight Gain ◽

Continuation Phase ◽

Factors Affecting ◽

Tuberculosis Patients ◽

End Of Treatment ◽

Body Weights ◽

The Mean ◽

The Difference

Background: Wasting is a common feature in tuberculosis and treatment is aimed at achieving weight gain in pulmonary tuberculosis patients. The aims and objectives of the study were to study the extent of body weight gain during treatment and to identify the effect of different factors on weight gain among TB patients.Methods: The study was conducted on a total of 326 patients residing in the area of PHC Verka and registered with District Tuberculosis Centre, Amritsar. Weight change was assessed by taking the difference of weight at initial diagnosis and after completion of continuation phase therapy.Results: A total of 228 patients participated in the study. The mean (±SD) body weights (in kg) for the patients were 44.92±12.7 at diagnosis and 48.79±12.9 at the end of treatment. The mean (±SD) weight gain was 3.86±4.55 kgs at the end of treatment. The gain in weight at the end of treatment was associated with supervision of treatment and outcome of the TB patient.Conclusions: The findings showed that there is an association between gain in weight with supervision of treatment and outcome of the TB patient.

Download Full-text

Determination some Immunological Aspects in Pulmonary Tuberculosis Patients in Qadisiyah Province

International Journal of Pharmaceutical Quality Assurance ◽

10.25258/ijpqa.v9i2.13632 ◽

2018 ◽

Vol 9 (2) ◽

Author(s):

Syoof Khowman Alramahy ◽

Akram Hadi Hamza

Keyword(s):

Mycobacterium Tuberculosis ◽

Pulmonary Tuberculosis ◽

Statistical Difference ◽

Positive Culture ◽

Control Group ◽

Tuberculosis Patients ◽

Significant Difference ◽

Lowenstein Jensen ◽

The Mean ◽

Igg Level

This study was carried out to study of some immunological aspects among the pulmonary Tuberculosis patients infected with causative agent, Mycobacterium tuberculosis. A Total of 200 sputum samples were collected from patients attending the consultant Clinic for Chest and Respiratory disease center, Diwaniya. Control group (No=15) also included. According to acid fast stain of sputum, the patients were classified as positive (No=91,45.5%) and negative (No=109,54.5, Lowenstein Jensen medium used for the cultivation of samples, on which 70% of sputum samples where positive culture for this microorganism. The grown microorganism were identified as M. tuberculosis, based on positive A.F.B, Niacin producers ,negative for catlase at 68c. The mean IgG level was l184.053±76.684 mg/100 ml in tuberculosis group compared with 1016.533 ± 44.882 mg/100ml in control group, rendering the statistical difference significant. For IgA and IgM levels, they were at mean of 315.880±38.552 mg/100 ml and 119.527±8.464 mg/100 ml in control group compared with 396.358±38.776 mg/100 ml and 134.207±11.696 mg/100 ml in patients group respectively with significant difference

Download Full-text

Evaluation of Commercial DNA and rRNA Amplification Assays for Assessment of Treatment Outcome in Pulmonary Tuberculosis Patients

European Journal of Clinical Microbiology & Infectious Diseases ◽

10.1007/s100960100593 ◽

2001 ◽

Vol 20 (10) ◽

pp. 746-750 ◽

Cited By ~ 1

Author(s):

I. Rajalahti ◽

P. Vuorinen ◽

K. Liippo ◽

M. Nieminen ◽

A. Miettinen

Keyword(s):

Treatment Outcome ◽

Pulmonary Tuberculosis ◽

Tuberculosis Patients

Download Full-text

Effects of Different Integrase Inhibitors on Body Weight in Patients with HIV/AIDS: A Network Meta-Analysis

10.21203/rs.3.rs-136545/v1 ◽

2020 ◽

Author(s):

Ruojing Bai ◽

Shiyun Lv ◽

Hao Wu ◽

Lili Dai

Keyword(s):

Body Weight ◽

Weight Gain ◽

Meta Analysis ◽

Biomedical Literature ◽

Cochrane Library ◽

Weight Changes ◽

Aids Patients ◽

First Choice ◽

Significant Difference ◽

Hiv Aids

Abstract Background: Global antiretroviral therapy has entered the era of integrase strand transfer inhibitor (INSTI). Because INSTIs have the advantages of high antiviral efficacy, rapid virus inhibition, and good tolerance, they have become the first choice in international acquired immunodeficiency syndrome (AIDS) treatment guidelines. However, they may also increase the risk of obesity. There are differences in the effects of different INSTIs on weight gain in Human immunodeficiency virus (HIV) infection / AIDS patients, but there is no evidence-based medical evidence. This study aimed to assess the effect of different INSTIs on body weight in HIV/AIDS patients.Methods: PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database, and Wanfang databases were searched by computer to screen the relevant literature on INSTI treatment of HIV/AIDS patients, extract the data on weight changes in the literature, and perform network meta-analysis using Stata16.0 software.Results: Eight articles reported weight changes in HIV/AIDS patients, and weight gain was higher after treatment with dolutegravir (DTG) than with elvitegravir (EVG) in HIV/AIDS patients, and the difference was statistically significant [MD = 1.13, (0.18, 2.07)]. The network meta-analysis's consistency test results showed no overall and local inconsistency, and there was no significant difference in the results of the direct and indirect comparison (P > 0.05). The rank order of probability was DTG (79.2%) > Bictegravir (BIC) (77.9%) > Raltegravir (RAL) (33.2%) > EVG (9.7%), suggesting that DTG may be the INSTI drug that causes the most significant weight gain in HIV/AIDS patients.Conclusion: According to the literature data analysis, among the existing INSTIs, DTG may be the drug that causes the highest weight gain in HIV/AIDS patients, followed by BIC.

Download Full-text

The Effect of Side Effects Tuberculosis Treatment in the Early Stage Towards Compliance with Tuberculosis Patients

Health Notions ◽

10.33846/hn50106 ◽

2021 ◽

Vol 5 (01) ◽

pp. 29-32

Author(s):

Joko Sapto Pramono ◽

Nilam Noorma ◽

Andi Lis Arming Gandini ◽

Sopia Fitriani

Keyword(s):

Side Effects ◽

Pulmonary Tuberculosis ◽

Health Workers ◽

Early Stage ◽

Treatment Compliance ◽

Tuberculosis Treatment ◽

Cross Sectional ◽

Tuberculosis Patients ◽

Early Stages ◽

Significant Difference

Pulmonary tuberculosis treatment causes various side effects including nausea and vomiting, itching, vision problems, and anemia. Drug side effects in the early stages are one of the causes of non-adherence to complete treatment. The purpose of this study was to analyze the effect of the side effects Tuberculosis treatment in the early stages on treatment compliance for tuberculosis patients. This study used a cross sectional design. Samples were taken as many as 71 respondents, the instruments used were side effects of early-stage tuberculosis treatment and compliance with tuberculosis treatment in tuberculosis patients from the Morisky Medication Adherence Scale (MMAS). The results of the study found 97.7% adherent and 2.3% non-adherent, 39.5% mild side effects and 60.5% severe side effects. Chi-square test showed that no significant difference between the side effects of TB treatment in the early stages of tuberculosis treatment compliance in patients p = 0.669 at significant level of 95% (α = 0.05). There was no effect between the side effects of Tuberculosis treatment in the early stages of treatment compliance for Tuberculosis patients. It was recommended that health workers continue to monitor the side effects of tuberculosis treatment and provide motivation to carry out treatment completely. Keywords: side effects; early stage; treatment; pulmonary tuberculosis; compliance

Download Full-text

Penggunaan Hasil Fermentasi Bungkil Kedelai Dalam Ransum Terhadap Pertumbuhan Ayam Pedaging

Jurnal Agripet ◽

10.17969/agripet.v2i2.3154 ◽

2001 ◽

Vol 2 (2) ◽

pp. 26-31

Author(s):

Al Qudri

Keyword(s):

Body Weight ◽

Weight Gain ◽

Soybean Oil ◽

Energy Content ◽

Body Weight Gain ◽

The Body ◽

Feed Consumption ◽

Feed Conversion ◽

Fermented Soybean ◽

Significant Difference

ABSTRACT. Tempe of soybean is fermented soybean with Rhizopus ologosporus fungus. From a result of researchers, it is the fact that tempe can increase valuable of nutrion and digest capacity and also produce antibiotic . Utilization of abtibiotic in chiken food as stimulus growth in not recommended because it can cause resistance a certain germ and it is presume there are antibiotic residu in egg and chiken meat. It is hope that the use of fermented soybean oil meal can increase nutrient value and digest capacity as well as produce antibiotic, so that it can get a better growth and over come a problem of using antibiotic in chiken food. The study was conducted to evaluate the effect of fermented soybean oil meal utilization in the ration on body weight gain, feed consumption, feed conversion and mortality. The study use 80 unsex day old chick broiler CP-707 and conducted at Poulty Laboratory Product Agriculture Faculty, Syiah Kuala University. Chiken were putting in 27 houses unit, each unit contain of four chiken. The design of experiment was Completely Randomized Design, four treatments and five replication. The treatments were ration contained 0%, 5%, 10% and 15% fermented soybean oil meal as replace the use of soybean oil meal. The protein and energy content of all dietary treatments were equally composed from six weeks investigation, were body weight gain, feed consumption, feed conversion and mortality. The result of the study indicated that up to 10% graded of fermented soybean oil meal in ration were significant difference influenced increase the body weight gain and decrease the feed conversion. The fermented soybeanoil meal) utilization more than 10% were significant difference decrease the body weight gain and increase the feed conversion. If the inclusion was increase the feed consumption would tendency decline. In this study there were no mortality in all treatment. In can be advised from this study that fermented soybean oil meal could be used in broiler ration or in all poulty ration.

Download Full-text

White tea drink (Camellia sinensis) improves endurance and body weight maintenance of rats

Journal of Health Research ◽

10.1108/jhr-01-2020-0020 ◽

2020 ◽

Vol ahead-of-print (ahead-of-print) ◽

Author(s):

Mahmud Aditya Rifqi ◽

Stefania Widya Setyaningtyas ◽

Qonita Rachmah

Keyword(s):

Body Weight ◽

Weight Gain ◽

Beneficial Effect ◽

Camellia Sinensis ◽

Intervention Research ◽

The Body ◽

Human Intervention ◽

Content Type ◽

White Tea ◽

Significant Difference

PurposeWhite tea is an unfermented tea made from young shoots of Camellia sinensis protected from sunlight to avoid polyphenol degradation. White tea contains a high level of polyphenolic compounds known as catechins. Several types of evidence have suggested that tea consumption has benefits in body weight and endurance maintenance. This study was designed to evaluate the effect of white tea on body weight and endurance of animal models.Design/methodology/approachThis research was an intervention design using 20 Wistar white rats (Rattus Norvegicus) in body weight between 150 and 200 g. The rats were randomized into four groups, three groups receiving white tea drink (WTD) with different doses and the other group receiving plain water in equal volume as a control group for four weeks. The forced swim test (FST) was done to measure their struggling capacity, and digital bodyweight to measure the weight.FindingsIntervention (WTD Groups and Control) caused weight gain among except G3 with the highest doses of white tea. The result showed that WTD intake in G3 had a significant difference (p < 0.05) on body weight gain compared to control. The authors found that WTD in a specific dose (G3: 0.22 mg) tends to maintain the body weight of animals (219.2 ± 41.96; 212.6 ± 46.90, respectively), while other doses caused weight gain. WTD also significantly increased the swimming and struggling capacity of rats that represented improvements the endurance along with the test. There was a statistically significant difference in endurance among all groups (p < 0.05).Research limitations/implicationsThe results of this study can be followed as human intervention research as an input for nutritionists and sports scientists to explore the beneficial effect of white tea.Practical implicationsThe results of this study can be followed as human intervention research as an input for nutritionists and sports scientists to explore the beneficial effect of white tea.Originality/valueThis study adds more evidence and information about the advantages of white tea as potential beverages in future healthy lifestyles.

Download Full-text

Weight changes during chemotherapy for breast cancer

Sao Paulo Medical Journal ◽

10.1590/s1516-31802002000400005 ◽

2002 ◽

Vol 120 (4) ◽

pp. 113-117 ◽

Cited By ~ 25

Author(s):

Luciano José Megale Costa ◽

Paulo César Spotti Varella ◽

Auro del Giglio

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Body Weight ◽

Weight Gain ◽

Weight Change ◽

Prognostic Significance ◽

Disease Free Survival ◽

Weight Changes ◽

Free Survival ◽

Disease Free

CONTEXT: Patients receiving adjuvant chemotherapy for breast cancer have a tendency to gain weight. This tendency has determining factors not completely defined and an unknown prognostic impact. OBJECTIVE: To evaluate weight change during chemotherapy for breast cancer in a defined population and to identify its predisposing factors and possible prognostic significance. DESIGN: Observational, retrospective cohort study. SETTING: Private clinical oncology service. PARTICIPANTS: 106 consecutive patients with breast cancer treated between June 1994 and April 2000, who received neoadjuvant (n = 8), adjuvant (n = 74) or palliative (n = 24) chemotherapy. INTERVETION: Review of medical records and gathering of clinical information, including patients’ body weights before treatment and at follow-up reviews. MAIN MEASUREMENTS: Body weight change, expressed as percentage of body weight per month in treatment; role of clinical data in weight change; and influence of weight change in overall survival and disease-free survival. RESULTS: There was a mean increase of 0.50 ± 1.42% (p = 0.21) of body weight per month of treatment. We noted a negative correlation between metastatic disease and weight gain (r = -0.447, p < 0.0001). In the adjuvant and neoadjuvant therapy groups there was a mean weight gain of 0.91 ± 1.19 % (p < 0.00001) per month, whereas in the metastatic (palliative) group, we observed a mean loss of 0.52 ± 1.21% (p = 0.11) of body weight per month during the treatment. We did not observe any statistically significant correlation between weight changes and disease-free survival or overall survival. CONCLUSIONS: Women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy gain weight, whereas metastatic cancer patients will probably lose weight during palliative chemotherapy. Further studies are needed in order to evaluate the prognostic significance of weight changes during chemotherapy.

Download Full-text